Direct phosphorylation of proliferative and survival pathway proteins by RET

Ganesh R. Panta, Lihua Du, Fiemu E. Nwariaku, Lawrence T. Kim

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background. Gain-of-function mutations in the RET tyrosine kinase receptor cause the multiple endocrine neoplasia syndromes type 2a and 2b, and medullary thyroid cancer. We have previously shown that RET signals through focal adhesion kinase (FAK) in medullary thyroid cancer cells and that extracellular signal-regulated kinase (ERK) activity can be blocked by pp2, an inhibitor of both Src and RET. We hypothesized that RET could directly phosphorylate FAK and ERK. Methods. RET and ERK kinase activity were measured with the use of an in vitro kinase assay. The relative contribution of RET in phosphorylation of ERK was tested by treating cells with PD98059, an inhibitor of MEK, and the RET inhibitor PP2, then measuring ERK activity. Results. Immunoprecipitated, mutant RET from cells or the recombinant RET kinase domain was able to directly phosphorylate tyrosine residues on FAK. Specifically Y576/577, Y861, and Y925, but not the autophosphorylation site Y397 of FAK, were phosphorylated by RET. Similarly ERK 2 could be phosphorylated at Y187 (Y204 in ERK1). Inhibition of both MEK (upstream of ERK) and RET was more potent than inhibition of either alone in decreasing ERK activity. Furthermore, tyrosine residues in DOK1, the p85 subunit of phosphatidylinositol 3′ kinase, JNK 1 and 2, P-38, and phospholipase-γ were directly phosphorylated by RET. Conclusions. RET directly phosphorylates tyrosine residues on FAK, ERK 1/2, DOK1, the p85 subunit of of phosphatidylinositol 3′ kinase, JNK 1 and 2, P-38, and phospholipase-γ. These data indicate a direct interaction between RET and a broad range of effector molecules that may contribute to tumor pathogenesis.

Original languageEnglish (US)
Pages (from-to)269-274
Number of pages6
JournalSurgery
Volume138
Issue number2
DOIs
StatePublished - Aug 2005

Fingerprint

Extracellular Signal-Regulated MAP Kinases
Focal Adhesion Protein-Tyrosine Kinases
Phosphorylation
Phosphatidylinositol 3-Kinase
Proteins
Tyrosine
Phosphotransferases
Phospholipases
Mitogen-Activated Protein Kinase 1
Mitogen-Activated Protein Kinase Kinases
Proto-Oncogene Proteins c-ret
Multiple Endocrine Neoplasia Type 2b
Multiple Endocrine Neoplasia Type 2a
Multiple Endocrine Neoplasia
Mitogen-Activated Protein Kinase 3
Mutation
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Direct phosphorylation of proliferative and survival pathway proteins by RET. / Panta, Ganesh R.; Du, Lihua; Nwariaku, Fiemu E.; Kim, Lawrence T.

In: Surgery, Vol. 138, No. 2, 08.2005, p. 269-274.

Research output: Contribution to journalArticle

Panta, Ganesh R. ; Du, Lihua ; Nwariaku, Fiemu E. ; Kim, Lawrence T. / Direct phosphorylation of proliferative and survival pathway proteins by RET. In: Surgery. 2005 ; Vol. 138, No. 2. pp. 269-274.
@article{71693b63e78e4ce193394829d3804c9d,
title = "Direct phosphorylation of proliferative and survival pathway proteins by RET",
abstract = "Background. Gain-of-function mutations in the RET tyrosine kinase receptor cause the multiple endocrine neoplasia syndromes type 2a and 2b, and medullary thyroid cancer. We have previously shown that RET signals through focal adhesion kinase (FAK) in medullary thyroid cancer cells and that extracellular signal-regulated kinase (ERK) activity can be blocked by pp2, an inhibitor of both Src and RET. We hypothesized that RET could directly phosphorylate FAK and ERK. Methods. RET and ERK kinase activity were measured with the use of an in vitro kinase assay. The relative contribution of RET in phosphorylation of ERK was tested by treating cells with PD98059, an inhibitor of MEK, and the RET inhibitor PP2, then measuring ERK activity. Results. Immunoprecipitated, mutant RET from cells or the recombinant RET kinase domain was able to directly phosphorylate tyrosine residues on FAK. Specifically Y576/577, Y861, and Y925, but not the autophosphorylation site Y397 of FAK, were phosphorylated by RET. Similarly ERK 2 could be phosphorylated at Y187 (Y204 in ERK1). Inhibition of both MEK (upstream of ERK) and RET was more potent than inhibition of either alone in decreasing ERK activity. Furthermore, tyrosine residues in DOK1, the p85 subunit of phosphatidylinositol 3′ kinase, JNK 1 and 2, P-38, and phospholipase-γ were directly phosphorylated by RET. Conclusions. RET directly phosphorylates tyrosine residues on FAK, ERK 1/2, DOK1, the p85 subunit of of phosphatidylinositol 3′ kinase, JNK 1 and 2, P-38, and phospholipase-γ. These data indicate a direct interaction between RET and a broad range of effector molecules that may contribute to tumor pathogenesis.",
author = "Panta, {Ganesh R.} and Lihua Du and Nwariaku, {Fiemu E.} and Kim, {Lawrence T.}",
year = "2005",
month = "8",
doi = "10.1016/j.surg.2005.04.007",
language = "English (US)",
volume = "138",
pages = "269--274",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Direct phosphorylation of proliferative and survival pathway proteins by RET

AU - Panta, Ganesh R.

AU - Du, Lihua

AU - Nwariaku, Fiemu E.

AU - Kim, Lawrence T.

PY - 2005/8

Y1 - 2005/8

N2 - Background. Gain-of-function mutations in the RET tyrosine kinase receptor cause the multiple endocrine neoplasia syndromes type 2a and 2b, and medullary thyroid cancer. We have previously shown that RET signals through focal adhesion kinase (FAK) in medullary thyroid cancer cells and that extracellular signal-regulated kinase (ERK) activity can be blocked by pp2, an inhibitor of both Src and RET. We hypothesized that RET could directly phosphorylate FAK and ERK. Methods. RET and ERK kinase activity were measured with the use of an in vitro kinase assay. The relative contribution of RET in phosphorylation of ERK was tested by treating cells with PD98059, an inhibitor of MEK, and the RET inhibitor PP2, then measuring ERK activity. Results. Immunoprecipitated, mutant RET from cells or the recombinant RET kinase domain was able to directly phosphorylate tyrosine residues on FAK. Specifically Y576/577, Y861, and Y925, but not the autophosphorylation site Y397 of FAK, were phosphorylated by RET. Similarly ERK 2 could be phosphorylated at Y187 (Y204 in ERK1). Inhibition of both MEK (upstream of ERK) and RET was more potent than inhibition of either alone in decreasing ERK activity. Furthermore, tyrosine residues in DOK1, the p85 subunit of phosphatidylinositol 3′ kinase, JNK 1 and 2, P-38, and phospholipase-γ were directly phosphorylated by RET. Conclusions. RET directly phosphorylates tyrosine residues on FAK, ERK 1/2, DOK1, the p85 subunit of of phosphatidylinositol 3′ kinase, JNK 1 and 2, P-38, and phospholipase-γ. These data indicate a direct interaction between RET and a broad range of effector molecules that may contribute to tumor pathogenesis.

AB - Background. Gain-of-function mutations in the RET tyrosine kinase receptor cause the multiple endocrine neoplasia syndromes type 2a and 2b, and medullary thyroid cancer. We have previously shown that RET signals through focal adhesion kinase (FAK) in medullary thyroid cancer cells and that extracellular signal-regulated kinase (ERK) activity can be blocked by pp2, an inhibitor of both Src and RET. We hypothesized that RET could directly phosphorylate FAK and ERK. Methods. RET and ERK kinase activity were measured with the use of an in vitro kinase assay. The relative contribution of RET in phosphorylation of ERK was tested by treating cells with PD98059, an inhibitor of MEK, and the RET inhibitor PP2, then measuring ERK activity. Results. Immunoprecipitated, mutant RET from cells or the recombinant RET kinase domain was able to directly phosphorylate tyrosine residues on FAK. Specifically Y576/577, Y861, and Y925, but not the autophosphorylation site Y397 of FAK, were phosphorylated by RET. Similarly ERK 2 could be phosphorylated at Y187 (Y204 in ERK1). Inhibition of both MEK (upstream of ERK) and RET was more potent than inhibition of either alone in decreasing ERK activity. Furthermore, tyrosine residues in DOK1, the p85 subunit of phosphatidylinositol 3′ kinase, JNK 1 and 2, P-38, and phospholipase-γ were directly phosphorylated by RET. Conclusions. RET directly phosphorylates tyrosine residues on FAK, ERK 1/2, DOK1, the p85 subunit of of phosphatidylinositol 3′ kinase, JNK 1 and 2, P-38, and phospholipase-γ. These data indicate a direct interaction between RET and a broad range of effector molecules that may contribute to tumor pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=24344510296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24344510296&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2005.04.007

DO - 10.1016/j.surg.2005.04.007

M3 - Article

VL - 138

SP - 269

EP - 274

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 2

ER -